Insulet stock edges higher as investors weigh fund exits and valuation gap

Insulet Corporation stock (ISIN US45784P1012) has been trading slightly higher in recent sessions, with the diabetes technology specialist closing at USD 140.60 on Nasdaq on September 16, 2026 and moving to around USD 141.66 intraday on September 17, 2026, while investors reassess recent fund exits and valuation signals.

Fund exits and one-year underperformance

According to Yahoo Finance on September 17, 2026, Baron SMID Cap ETF reported in its second-quarter 2026 investor letter that it sold its holdings in Insulet Corporation, highlighting the stock’s sharp decline over the past year.

In that update, Insulet stock was reported to have closed at USD 140.60 on September 16, 2026 and to have fallen 57.84 percent over the preceding 52 weeks, underscoring how far the shares remain below earlier levels despite a recent recovery phase.Yahoo Finance

A separate valuation overview notes that Insulet’s latest close around USD 141.55 translated into a seven-day share price return of just over 5 percent, indicating short term buying interest even as the one-year total shareholder return is described as falling roughly 58 percent.Simply Wall St

Valuation gap and recent returns

The same Simply Wall St analysis calculates a fair value estimate for Insulet at about USD 171.91 per share versus a recent closing level of roughly USD 141.55, implying an undervaluation of around 21.3 percent based on that model.Simply Wall St For investors, this gap between market price and modeled fair value is a key part of the current Insulet stock story.

Price data from a Nasdaq overview show Insulet trading at about USD 141.66 on September 17, 2026 at 2:28 p.m. Eastern Time, up 0.75 percent on the day compared with a previous close of USD 140.60, with a day’s range between USD 138.51 and USD 141.64.Yahoo Finance

The same overview reports trailing total returns as of September 17, 2026, with a year-to-date return of 50.16 percent for Insulet compared with 11.58 percent for the S&P 500 index, and a one-year return of 56.04 percent for the stock against 15.72 percent for the index, highlighting that recent months have seen a strong bounce from earlier lows.Yahoo Finance

Business profile and upcoming investor event

Insulet develops, manufactures and sells insulin delivery systems, notably its Omnipod branded tubeless insulin pump technology for people with insulin-dependent diabetes in the United States and internationally, positioning the company in the fast-growing diabetes care and medical devices segment.Yahoo Finance

As a sign of ongoing investor engagement, Insulet announced that its management will present at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 24, 2026 at 12:30 p.m. Eastern Time, offering another opportunity for the market to hear directly from leadership about strategy and outlook.Business Wire

Stock level and performance snapshot

With Insulet stock recently changing hands around USD 141.66 on Nasdaq as of September 17, 2026, roughly 21.3 percent below the USD 171.91 fair value estimate discussed by Simply Wall St, the shares reflect both the impact of past drawdowns and the potential implied by valuation models and year-to-date outperformance.

More news and analyses on Insulet stock